Custirsen as Treatment for Prostate Cancer
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.
Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a phase III trial of custirsen (OGX-011) and its potential for treatment in patients with prostate cancer.
Clinical Pearls:
- A phase III trial of custirsen in combination with docetaxel has been conducted and results are expected to be available within a year
- Based on a phase II trial, the combination appeared to be more effective than docetaxel when used as mono therapy
- This phase III trial will determine if custirsen plus docetaxel is more effective than docetaxel alone for patients with castration-resistant prostate cancer
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
